NL-OMON27637招募中不适用
Prediction of benralizumab response in severe asthma using clinical parameters and early treatment response:a national, real life study
Medical Centre Leeuwarden0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Included in RAPSODI, receiving benralizumab treatment
- •RAPSODI inclusion criteria:
- •- Severe asthma patient in the Netherlands
- •- =18 years old
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Predictive Signature of Benralizumab Response. BENRAPRED Study.Severe asthmaMedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2024-514843-27-00Centre Hospitalier Universitaire De Nantes220
招募中
4 期
Predictive Signature of Benralizumab Response. BENRAPRED Study.2024-514843-27-00Centre Hospitalier Universitaire De Nantes220
招募中
4 期
BenRalizumab Effect on Airway Remodeling in Severe asTHmaAirway RemodelingEosinophilic AsthmaNCT06288516Aristotle University Of Thessaloniki45
已完成
4 期
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingAsthmaNCT05552508AstraZeneca45
进行中（未招募）
1 期
Reslizumab in patients with severe asthma who failed to respond to omalizumabSevere asthmaMedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-004459-65-ESRespira. Fundación Española del Pulmón (SEPAR)